Table 7. Summary of urine protein biomarkers for pancreatic and biliary tract cancer, 2013–2017.
| Author (year) | Biomarker/
Combination (urine) |
Pancreatic ductal
adenocarcinoma, number |
Biliary tract
cancer, number |
Benign
cancer/ Chronic pancreatitis, number |
Healthy
volunteers, number |
Sensitivity | Specificity | Area
under the curve |
|
|---|---|---|---|---|---|---|---|---|---|
| Single biomarker | |||||||||
| Roy et al. (2014) 172 | MMP2 | 51 | - | - | 60 | 70% | 85% | - | |
| Roy et al. (2014) 172 | TIMP-1 | 51 | - | - | 60 | 90% | 70% | - | |
| Jiao et al. (2014) 96 | Nucleosides | - | 202
(gallbladder cancer) |
203 | 205 | 89.4% | 97.1% | - | |
| Metzger et al. (2013) 42 | Urine Proteomic
analysis |
- | 42 | 81 | - | 83% | 79% | 0.87 | |
| Biomarker combinations | |||||||||
| Radon et al. (2015) 43 | LYVE-1 +
REG1A + TFF1 |
192 | - | - | 87 | - | - | 0.89 | |